Business Wire

University Politehnica of Bucharest Opens First International NuScale Power Energy Exploration Center

12.5.2023 17:15:00 EEST | Business Wire | Press release

Share

NuScale Power Corporation (NYSE: SMR) announced today the opening of a NuScale Energy Exploration Center (E2 Center) at University Politehnica of Bucharest in support of a collaboration with the United States and Romanian governments, and S.N. Nuclearelectrica S.A. (Nuclearelectrica). Key government officials attended the opening, including U.S. Ambassador to Romania Kathleen Kavalec, Romania Prime Minister Nicolae Ciuca, and Romanian Minister of Energy Virgil Popescu. As the first international E2 Center, this workforce development tool will enable Romania to develop the next generation of advanced nuclear experts, technologists, and operators and become a hub for deploying small modular reactors (SMR) in Europe.

“NuScale’s SMR nuclear technology is the premier global clean energy solution and can help advance Romania’s position as a leader in the secure and safe deployment of SMRs,” said John Hopkins, NuScale President and Chief Executive Officer. “With the support of the DOS under the FIRST program, we are thrilled to hit another milestone in this remarkable collaboration among our countries and organizations. We look forward to supporting the next generation of clean energy leaders across the region and around the globe.”

The E2 Center was funded by the U.S. Department of State (DOS) under the Foundational Infrastructure for the Responsible Use of Small Modular Reactor Technology (FIRST) program. FIRST supports partner countries in advancing their nuclear energy programs to meet their clean energy goals under the highest international standards for nuclear safety, security, and nonproliferation.

"The SMR project at Doicesti, which this E2 Center supports, will showcase Romanian leadership in energy innovation, accelerate the clean energy transition, create thousands of jobs in Romania and the U.S., and strengthen European energy security while upholding the highest standards for nuclear safety, security, and nonproliferation,” said Ann Ganzer, Principal Deputy Assistant Secretary, Bureau of International Security and Nonproliferation.

This announcement builds upon NuScale Power and Nuclearelectrica’s teaming agreement signed in 2021 to deploy a 462 MWe NuScale VOYGRTM-6 power plant in Romania by the end of the decade. Earlier this year, NuScale and RoPower Nuclear S.A. (RoPower), owned in equal shares by Nuclearelectrica and Nova Power & Gas S.A., commenced front-end engineering and design work for a site in Doicesti, Romania, the preferred location for the deployment of the VOYGR power plant.

Romania has the potential to be one of the first deployments of an SMR in Europe and to become a catalyst for SMRs in the region by serving as a base for supporting operations of this new technology in other countries, as well as the production and assembly of plant components.

“Building on the strong nuclear experience in safe operations for more than 26 years, we are proud to support Romania’s workforce development in the nuclear sector for a new technologically advanced future. Nuclearelectrica has outstanding specialists and operational performance, and is internationally recognized, which not only places Romanian nuclear industry as a top performer, but also as the foundation for Romania’s leadership in nuclear energy. Nuclearelectrica has strong assets, which qualifies us to be the first country after the U.S. to deploy a NuScale SMR. The first E2 Center launched in Romania is only the beginning of this new era in technology, human resources, safe, affordable clean energy, with multiple benefits for communities and industries, to which we are happy to contribute,” Cosmin Ghita, Chief Executive Officer of Nuclearelectrica.

“Nuclear energy and SMRs are included in Romania’s energy strategy as a main pillar for energy security and reaching our decarbonation targets. Our commitment to increase energy production from clean nuclear energy sources will create much needed complementarity with renewable resources, increase flexibility in the system, and allow further complex development of former coal-based facilities. The 26 years of Romanian safe operation expertise are the basis for further developing Romania’s nuclear energy program. The energy transition is not possible without maintaining and expanding the role of nuclear power and it requires strong international partnerships, like the one we are enhancing today. I thank our American partners for their continuous support, Nuclearelectrica for its leadership in the industry and capability to take on the journey to become a regional preferred operator, and University of Politehnica for their dedication towards performance and workforce development. I want to give a clear message: The Romanian Prime Minister Nicolae Ciuca, our Government, and Romanian President Klaus Iohannis strongly support the development of nuclear energy and the effort to form experts in this domain,” said Virgil Popescu, Minister of Energy, Romania.

The E2 Center is an innovative learning environment that offers users a hands-on opportunity to apply nuclear science and engineering principles through simulated, real-world nuclear power plant operation scenarios. The E2 Center employs state-of-the-art computer modeling to simulate a NuScale VOYGR SMR power plant control room. Users have the opportunity to take on the role of a “Control Room Operator” at a VOYGR plant to learn about the advanced operational and safety features unique to NuScale’s technology.

The University Politehnica of Bucharest is one of the elite schools of the Romanian higher education system. The school was established in 1950, and offers highly appreciated academic studies and programs for more than 2,000 students a year.

About NuScale Power

NuScale Power Corporation (NYSE: SMR) is the industry-leading provider of proprietary and innovative advanced small modular reactor nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. The company’s groundbreaking VOYGR™ SMR plants are powered by the NuScale Power Module™, a small, safe, pressurized water reactor that can each generate 77 megawatts of electricity (MWe) or 250 megawatts thermal (gross), and can be scaled to meet customer needs through an array of flexible configurations up to 924 MWe (12 modules) of output.

As the first and only SMR to have its design certified by the U.S. Nuclear Regulatory Commission, NuScale is well-positioned to serve diverse customers across the world by supplying nuclear energy for electrical generation, district heating, desalination, commercial-scale hydrogen production, and other process heat applications.

Founded in 2007, NuScale is headquartered in Portland, Ore. To learn more, visit NuScale Power’s website or follow us on Twitter , Facebook , LinkedIn , Instagram and YouTube .

Forward Looking Statements

This release may contain “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical facts. These forward-looking statements are inherently subject to risks, uncertainties and assumptions. Actual results may differ materially as a result of a number of factors. Caution must be exercised in relying on these and other forward-looking statements. Due to known and unknown risks, NuScale’s results may differ materially from its expectations and projections. NuScale specifically disclaims any obligation to update these forward-looking statements. These forward-looking statements should not be relied upon as representing NuScale’s assessments as of any date subsequent to the date of this release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Diane Hughes, Vice President, Marketing & Communications, NuScale Power
dhughes@nuscalepower.com
(503) 270-9329

Investor Contact
Scott Kozak, Director, Investor Relations, NuScale Power
skozak@nuscalepower.com
(541) 452-7583

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye